Risk factors and incidence of new-onset heart failure with conventional pacemaker implant: A nationwide study

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Heart Rhythm O2 Pub Date : 2024-09-01 DOI:10.1016/j.hroo.2024.07.012
{"title":"Risk factors and incidence of new-onset heart failure with conventional pacemaker implant: A nationwide study","authors":"","doi":"10.1016/j.hroo.2024.07.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Studies have shown that the risk of new-onset heart failure (HF) is higher postimplantation for patients receiving right ventricular pacing.</p></div><div><h3>Objective</h3><p>This study aimed to investigate incidence, risk factors, and implications for long-term prognosis of new-onset HF in patients after pacemaker implantation.</p></div><div><h3>Methods</h3><p>Patients without pre-existing HF who received a pacemaker in Sweden during the period of 2005 to 2020 were identified via the nationwide Pacemaker Registry. Data were crossmatched with the population registry and national disease registries. The primary outcome was new-onset HF within 5 years, and a risk score for this was developed and validated.</p></div><div><h3>Results</h3><p>In all, 65,579 patients met the inclusion criteria (10,351 single-chamber ventricular and 55,228 dual-chamber pacemakers). A total of 13,792 (21.0%) patients were diagnosed with HF within 5 years postimplantation. Of these, 6244 (45.3%) were hospitalized for HF. Patients with new-onset HF were more likely to die within 5 years (41.2% vs 19.7%, <em>P</em> &lt; .0001). Risk factors for new-onset HF included increasing age, male sex, hypertension, diabetes, atrial fibrillation, chronic lung and kidney disease, ischemic heart disease, and atrioventricular block. In a combined score using these variables, patients in the highest risk-score quartile had a hazard ratio of 5.36 (95% CI 4.91–5.86, <em>P</em> &lt; .001) and an absolute risk of 32% for developing HF.</p></div><div><h3>Conclusion</h3><p>Pacemaker therapy is associated with &gt;20% risk of new-onset HF within 5 years, and we identified 9 risk factors associated with the diagnosis of new-onset HF. The proposed score based on these variables can be used to identify patients at high risk for new-onset HF.</p></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666501824002319/pdfft?md5=f4bd3c7ed40e19ea0e6aad4ea60c42f8&pid=1-s2.0-S2666501824002319-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart Rhythm O2","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666501824002319","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Studies have shown that the risk of new-onset heart failure (HF) is higher postimplantation for patients receiving right ventricular pacing.

Objective

This study aimed to investigate incidence, risk factors, and implications for long-term prognosis of new-onset HF in patients after pacemaker implantation.

Methods

Patients without pre-existing HF who received a pacemaker in Sweden during the period of 2005 to 2020 were identified via the nationwide Pacemaker Registry. Data were crossmatched with the population registry and national disease registries. The primary outcome was new-onset HF within 5 years, and a risk score for this was developed and validated.

Results

In all, 65,579 patients met the inclusion criteria (10,351 single-chamber ventricular and 55,228 dual-chamber pacemakers). A total of 13,792 (21.0%) patients were diagnosed with HF within 5 years postimplantation. Of these, 6244 (45.3%) were hospitalized for HF. Patients with new-onset HF were more likely to die within 5 years (41.2% vs 19.7%, P < .0001). Risk factors for new-onset HF included increasing age, male sex, hypertension, diabetes, atrial fibrillation, chronic lung and kidney disease, ischemic heart disease, and atrioventricular block. In a combined score using these variables, patients in the highest risk-score quartile had a hazard ratio of 5.36 (95% CI 4.91–5.86, P < .001) and an absolute risk of 32% for developing HF.

Conclusion

Pacemaker therapy is associated with >20% risk of new-onset HF within 5 years, and we identified 9 risk factors associated with the diagnosis of new-onset HF. The proposed score based on these variables can be used to identify patients at high risk for new-onset HF.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
常规起搏器植入后新发心力衰竭的风险因素和发病率--一项全国性研究
背景研究表明,接受右心室起搏的患者在植入起搏器后新发心力衰竭(HF)的风险较高。方法通过全国起搏器登记处确定 2005 年至 2020 年期间在瑞典接受起搏器治疗的无 HF 患者。数据与人口登记和国家疾病登记进行交叉比对。结果共有65579名患者符合纳入标准(10351名单腔心室起搏器患者和55228名双腔起搏器患者)。共有 13,792 名患者(21.0%)在植入后 5 年内被诊断出患有心房颤动。其中 6244 人(45.3%)因心房颤动住院。新发心房颤动患者更有可能在 5 年内死亡(41.2% vs 19.7%,P < .0001)。新发 HF 的风险因素包括年龄增长、男性、高血压、糖尿病、心房颤动、慢性肺病和肾病、缺血性心脏病和房室传导阻滞。结论心脏起搏器治疗与 5 年内新发 HF 的>20%风险相关,我们发现了与新发 HF 诊断相关的 9 个风险因素。根据这些变量提出的评分标准可用于识别新发高血压的高危患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart Rhythm O2
Heart Rhythm O2 Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
0
审稿时长
52 days
期刊最新文献
A model for the development of cardiac implantable electronic device services in countries lacking such services A prospective, multicenter, randomized controlled trial comparing VDD-ICD with VVI-ICD in detecting subclinical atrial fibrillation in patients with ICDs: The Dx-AF trial Risk factors and incidence of new-onset heart failure with conventional pacemaker implant: A nationwide study Outcomes of patients with malignancy undergoing catheter ablation for ventricular tachycardia in the United States Remarkably high and accelerating failure rate of a widely used implantable cardioverter-defibrillator lead: A large-scale manufacturer-independent multicenter study with long accurate follow-up
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1